An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models

被引：0
|
作者：
Hu, S. [1 ]
Marineau, J. [1 ]
Bradley, M. [1 ]
Hamman, K. [1 ]
Alnemy, S. [1 ]
Smith, D. [1 ]
Carulli, J. [1 ]
Chuaqui, C. [1 ]
机构：
[1] Syros Pharmaceut Inc, Drug Discovery, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96 (PB-047
引用
收藏
页码：E39 / E40
页数：2
相关论文
共 50 条
  • [41] Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of glioblastoma
    Piggott, Luke
    Luong, Noemie
    Massiere, Frederic
    Kunze, Annett
    Chardonnens, Christophe
    Vaslin, Anne
    CANCER RESEARCH, 2023, 83 (07)
  • [42] Anti-tumor effect of taxol in oral cancer cell lines
    Myoung, H
    Kim, MJ
    JOURNAL OF DENTAL RESEARCH, 1999, 78 (05) : 1141 - 1141
  • [43] BMS-387032: A selective CDK2 inhibitor with potent anti-tumor activity.
    Misra, RN
    Xiao, HY
    Kim, KS
    Lu, SF
    Han, WC
    Rawlins, DB
    Shan, WF
    Ahmed, SZ
    Qian, L
    Chen, BC
    Zhao, RL
    Bednarz, MS
    Bursuker, I
    Kellar, KA
    Mulheron, JG
    Batorsky, R
    Roongta, U
    Sacks, JS
    Tokarski, JS
    Lee, FY
    Bol, DK
    Kamath, A
    Humphreys, WG
    Marathe, P
    Hunt, JT
    Pavletich, NP
    Kimball, SD
    Webster, KR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U176 - U176
  • [44] Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor
    Khare, Leena
    Poddutoori, Ramulu
    Mukherjee, Subhendu
    Samiulla, D. S.
    Devaraja, T. S.
    Marappan, Sivapriya
    Nayak, Shilpa
    Sivakumar, Sasirekha
    Kaza, Lakshmi
    Tgore, Suraj
    Dhudashiya, Amit
    Raghavendra, N. R.
    Gunnepalli, Bhargav
    Aravind, A. B.
    Amith, A.
    Charamanna, K. B.
    Antony, Thomas
    Nellore, Kavitha
    Daginakatte, Girish
    Chelur, Shekar
    Giri, Sanjeev
    Ramachandra, Murali
    Samajdar, Susanta
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [45] Anti-tumor activity of a MYC-targeting dicer substrate siRNA in combination with BRD4/CDK7 inhibitors
    Chipumuro, Edmond
    Siddiquee, Zakir
    Ganesh, Shanthi
    Shui, Serena
    Shah, Anee
    Kim, Boyoung
    Chen, Dongyu
    Pandya, Purva
    Storr, Rachel
    Wang, Weimin
    Dudek, Hank
    Lai, Cheng
    Abrams, Marc
    Brown, Bob
    CANCER RESEARCH, 2016, 76
  • [46] Anti-tumor effects of fadraciclib, CDK2/9 inhibitor, in biliary tract cancer
    Kim, Jae-Min
    Nam, Ah-Rong
    Oh, Kyoung-Seok
    Bang, Ju-Hee
    Jeong, Yoojin
    Choo, Sea Young
    Lee, Su In
    Kim, Hyo Jung
    Yoon, Jeesun
    Kim, Tae-Yong
    Oh, Do-Youn
    CANCER RESEARCH, 2024, 84 (06)
  • [47] Elacestrant (RAD1901) demonstrates anti-tumor activity in models resistant to CDK4/6 inhibitors
    Patel, H.
    Tao, N.
    Arlt, H.
    Bihani, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.
    Shapiro, Geoffrey
    Papadopoulos, Kyriakos P.
    Do, Khanh T.
    Juric, Dejan
    Jeseslsohn, Rinath
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    Hodgson, Graeme
    DiTomaso, Emmanuelle
    Stephens, Kristin
    Roth, David A.
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] ANTI-TUMOR EFFECT OF LIDOCAINE ON VARIOUS BREAST CANCER CELLS
    Chamaraux-Tran, Thien-nga
    Charton, Antoine
    Noll, Eric
    Pottecher, Julien
    Rio, Marie-Christine
    Geny, Bernard
    Mathelin, Carole
    Tomasetto, Catherine
    Diemunsch, Pierre
    ACTA PHYSIOLOGICA, 2015, 214 : 54 - 54
  • [50] A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma
    Zuo, Pengcheng
    Li, Yaopeng
    Wang, Tantan
    Lin, Xingyu
    Wu, Zhen
    Zhang, Junting
    Liao, Xuebin
    Zhang, Liwei
    JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (01) : 159 - 171
12345